INNOVIVA, INC. Current Assets
INNOVIVA, INC. (INVA) had Current Assets of $753.37 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-05
- 2026-06-30: Assets, Current $753.37M.
- 2026-03-31: Assets, Current $772.62M.
- 2025-12-31: Assets, Current $727.51M.
- 2025-09-30: Assets, Current $684.57M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $753.37M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $772.62M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $727.51M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $684.57M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $651.78M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $582.02M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $554.31M 10-K · filed 2026-02-25 |
| 2024-09-30 | $400.62M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $358.28M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $311.34M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $344.22M 10-K · filed 2025-02-26 |
| 2023-09-30 | $305.00M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $323.54M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $296.45M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $443.51M 10-K/A · filed 2024-03-05 |
| 2022-09-30 | $454.59M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $400.33M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $317.82M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $313.67M 10-K · filed 2023-02-28 |
| 2021-09-30 | $236.93M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $148.26M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $372.93M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $342.06M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $572.04M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $500.19M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $466.91M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $431.23M 10-K · filed 2021-02-25 |
| 2019-09-30 | $366.80M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $317.69M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $251.52M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $199.04M 10-K · filed 2020-02-19 |
| 2018-09-30 | $121.13M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $178.66M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $113.25M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $200.37M 10-K · filed 2019-02-19 |
| 2017-09-30 | $220.51M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $198.06M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $214.42M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $198.05M 10-K · filed 2018-02-23 |
| 2016-09-30 | $186.12M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $190.42M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $196.71M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $214.32M 10-K · filed 2017-02-28 |
| 2015-09-30 | $223.75M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $243.96M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $262.39M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $252.18M 10-K · filed 2016-02-24 |
| 2014-09-30 | $273.47M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $353.16M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $389.20M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $483.20M 10-K · filed 2015-02-27 |
| 2013-09-30 | $522.34M 10-Q · filed 2013-11-01 |
| 2013-06-30 | $457.23M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $474.51M 10-Q · filed 2013-05-01 |
| 2012-12-31 | $261.13M 10-K · filed 2014-03-03 |
| 2012-09-30 | $282.54M 10-Q · filed 2012-10-31 |
| 2012-06-30 | $303.38M 10-Q · filed 2012-08-01 |
| 2012-03-31 | $204.33M 10-Q · filed 2012-05-02 |
| 2011-12-31 | $244.76M 10-K · filed 2013-02-26 |
| 2011-09-30 | $269.17M 10-Q · filed 2011-11-02 |
| 2011-06-30 | $288.63M 10-Q · filed 2011-08-03 |
| 2010-12-31 | $316.35M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |